Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7263792 | 0.84 | S1PR3 (0.40) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| SCHEMBL2148491 | 0.82 | KDM4E (0.41) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| SCHEMBL2588895 | 0.82 | ADRA2A (0.38) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| SCHEMBL589541 | 0.82 | ADRA2A (0.38) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| SCHEMBL4901266 | 0.82 | KDM4E (0.41) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| SCHEMBL24234051 | 0.82 | GBA1 (0.38) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| SCHEMBL1063041 | 0.82 | ADRA2A (0.38) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| SCHEMBL1577349 | 0.82 | KDM4E (0.41) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| Hydrochloric Acid SCHEMBL1060426 | 0.80 | ADRA2A (0.40) | GBA1KDM4EALDH1A1S1PR4S1PR3 | |
| Ammonia Solution, Strong SCHEMBL7423037 | 0.80 | ADRA2A (0.37) | GBA1KDM4EALDH1A1S1PR4S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2023-08-31 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| EP-3870573-B1 | FUNCTIONALIZED AMINOTRIAZINES | LEADXPRO AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-11714080-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11692998-B2 | Compounds and methods of identifying, synthesizing, optimizing and profiling protein modulators | HMI Medical Innovations, LLC (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | PLIANT THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-7582770-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| WO-2009018657-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-12 | — | — | WO | disclosed |
| US-7371759-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371759-B2 | HMG-CoA reductase inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7157486-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | GBA1 2798/4885KDM4E 2459/4885ALDH1A1 4145/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GBA1 545/4885KDM4E 1618/4885ALDH1A1 2353/4885 |
| US-20230271960-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | GBA1 3249/4885KDM4E 3239/4885ALDH1A1 3834/4885 |
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | GBA1 1098/4885KDM4E 1381/4885ALDH1A1 3958/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | GBA1 260/4885KDM4E 4806/4885ALDH1A1 1201/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | GBA1 521/4885KDM4E 4525/4885ALDH1A1 1972/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | GBA1 1951/4885KDM4E 1352/4885ALDH1A1 2716/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | GBA1 834/4885KDM4E 3117/4885ALDH1A1 1556/4885 |
| US-20230181546-A1 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | ITGA5, ITGAL, ITGB5 | GBA1 2821/4885KDM4E 4191/4885ALDH1A1 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.